WINDTREE THERAPEUTICS INC /DE/

The company is a clinical-stage biotechnology enterprise dedicated to developing therapies for critical cardiovascular and oncology diseases. Its development pipeline features istaroxime, a Phase 2 drug candidate targeting acute heart failure and cardiogenic shock, alongside preclinical SERCA2a activators and rostafuroxin for hypertension. Through asset acquisitions, the organization also develops topical and oral formulations of atypical protein kinase C iota inhibitors aimed at cutaneous and solid tumor cancers. It operates an out-licensing model to partner on drug development and commercialization, while actively pursuing strategic acquisitions of small biotech firms with regulatory-approved commercial products.

The business manages clinical development operations and research collaborations internationally, including a regional licensing agreement covering Greater China and partnerships involving academic and charitable cancer research institutions located in the United Kingdom. Its cardiovascular clinical trials encompass global multi-center programs evaluating therapies across North America and Europe. The provided text does not disclose the location of the company's corporate headquarters or specific facility counts.

Summary of the business section of Windtree Therapeutics's latest annual report, written by StockData.

“As of April 15, 2025 , we had 14 full-time employees, 11 of whom are based in the U.S.”